@article{30c29cea12a74048bb5e637b704d9de1,
title = "Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts",
abstract = "Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.",
author = "Rengaswamy Sankaranarayanan and Partha Basu and Prabhdeep Kaur and Rajesh Bhaskar and Singh, {Gurinder Bir} and Phumzay Denzongpa and Grover, {Rajesh K.} and Paul Sebastian and Tapan Saikia and Kunal Oswal and Rishav Kanodia and Amantia Dsouza and Ravi Mehrotra and Rath, {Goura Kishor} and Viniita Jaggi and Sundram Kashyap and Ishu Kataria and Roopa Hariprasad and Peter Sasieni and Neerja Bhatla and Preetha Rajaraman and Trimble, {Edward L.} and Soumya Swaminathan and Arnie Purushotham",
note = "Funding Information: We identified and reviewed reports related to human papillomavirus vaccines published by the Indian Ministry of Health, Government of India, and Indian Council for Medical Research. References for this Policy Review were identified through searches of PubMed with the search terms “human papillomavirus vaccine”, “India”, and “immunization programme” for items published between Jan 1, 2007, and April 30, 2019. Articles were also identified through searches of the authors{\textquoteright} own files. Only items published in English were reviewed. The final reference list was generated on the basis of originality and relevance to the broad scope of this Policy Review. Contributors RS drafted the first version of the manuscript, participated in subsequent revisions, contributed to the final version of the manuscript, and was involved in the collection of data. PB, AP, PSe, and KO contributed extensively to the revision of the initial drafts, and were involved in literature review, collection of data, and finalisation of the manuscript for submission. PK, RB, GBS, PD, RKG, VJ, and SK provided data from Punjab (PK, RB, and GBS), Sikkim (PD), and Delhi (RKG, VJ, and SK) and contributed to the revision of the manuscript. IK contributed in writing the cost-effectiveness of HPV vaccination in India section and in revising and finalising the manuscript. TS, RM, RK, AD, RH, VJ, SK, GKR, PSe, NB, PR, ELT, PSa, and SS contributed to the collection of data and to revising and finalising the manuscript. Declaration of interests We declare no competing interests. Acknowledgments We are grateful to Srinivasan Selvamani, Sub Regional Team Leader (Chandigarh, Punjab, and Haryana, India) of the WHO National Polio Surveillance Project (NPSP), for leading the field team in Punjab, and Debashish Roy, Regional Team Leader (East Region) of the WHO NPSP, for leading the field team in Sikkim. We thank Krittika Guinot of the Screening Group, International Agency for Research on Cancer (Lyon, France) for her help in the preparation of the manuscript. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Funding Information: We are grateful to Srinivasan Selvamani, Sub Regional Team Leader (Chandigarh, Punjab, and Haryana, India) of the WHO National Polio Surveillance Project (NPSP), for leading the field team in Punjab, and Debashish Roy, Regional Team Leader (East Region) of the WHO NPSP, for leading the field team in Sikkim. We thank Krittika Guinot of the Screening Group, International Agency for Research on Cancer (Lyon, France) for her help in the preparation of the manuscript. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Publisher Copyright: {\textcopyright} 2019 World Health Organization. Published by Elsevier Ltd. All rights reserved.",
year = "2019",
month = nov,
doi = "10.1016/S1470-2045(19)30531-5",
language = "English (US)",
volume = "20",
pages = "e637--e644",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",
}